近日,一篇发表于国际著名杂志Nature上的研究论文中,来自芬兰赫尔辛基大学等处的研究人员通过研究发现辉瑞公司生产的药物阿西替尼的潜在未知的功能,研究者表示该药物或许可以作为显性突变的一种潜在抑制剂,而显性突变往往会引发特定类型的白血病患者出现药物耐受性。文章中,研究人员对来自慢性髓性白血病和急性淋巴细胞白血病患者机体的癌细胞进行分析研究,这些患者已经对当前的疗法产生了耐药 Recently, in a research paper published in the internationally renowned journal Nature, researchers from the University of Helsinki in Finland and other research institutes discovered through research that Pfizer’s potential unknown function of the drug axitinib, the researchers said the drug may be As a potential inhibitor of dominant mutations, dominant mutations often lead to drug resistance in specific types of leukemia. In the article, researchers analyzed cancer cells from patients with chronic myelogenous leukemia and acute lymphoblastic leukemia, and these patients have become resistant to current therapies